De-escalation
Formal Definition
The practice of narrowing antimicrobial therapy — switching from a broad-spectrum antibiotic to a targeted agent, or discontinuing agents — once culture and sensitivity results identify the causative pathogen and its susceptibility profile; a key antimicrobial stewardship principle to minimize collateral damage, resistance selection, and adverse effects.
How It's Used on the Ward
"De-escalate the antibiotics" or "narrow coverage" — stepping down from broad-spectrum to targeted therapy once cultures come back.
Example
""Blood cultures from day 1 grew MSSA — de-escalating from vancomycin to oxacillin now. MSSA is much better covered by beta-lactams and we'll get better pharmacokinetics with less toxicity.""
Clinical Context
De-escalation is one of the highest-yield antimicrobial stewardship interventions. Common de-escalation moves: vancomycin → oxacillin/nafcillin (for MSSA), pip-tazo → ampicillin-sulbactam (for sensitive organisms), carbapenem → narrower beta-lactam (for non-ESBL organisms). Barriers to de-escalation: physician discomfort with narrowing a "working" regimen, fragmented care, lack of culture follow-up. Pharmacy or ID stewardship teams often drive this actively.